ArticleJapanese journal of gastroenterology and hepatology2026
Dynamic Changes in Serum AFP, Albumin and ALBI after Radioembolization in Patients with Unresectable Hepatocellular Carcinoma with High or Low Alpha-Fetoprotein Levels.
Article in Japanese journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: 1.1.Yttrium-90 trans arterial radioembolization (TARE) is an established locoregional therapy for unresectable hepatocellular carcinoma (HCC). Baseline biomarkers are widely used for prognosis, but the clinical significance of post-TARE changes in tumour and liver-function biomarkers remains uncertain. ALBI and related measures have emerged as objective prognostic indices of hepatic reserve and HCC. Aim: 1.2.To identify early post-TARE biomarker changes associated with overall survival. Methods: 1.3.We retrospectively analysed 276 nonsurgical patients with HCC who underwent TARE and had available survival data. Changes in routinely measured tumour, inflammatory, hematologic, and liver-function variables were assessed at 1, 3, 6, and 12 months, when available. Results: 1.4.Biomarker changes were evident by 1 month, particularly in AFP, albumin, and ALBI grade, in patients with both low and high baseline AFP. Changes in PALBI, mALBI, GGT, CRP, and bilirubin were also observed. Increased or stable albumin was associated with longer survival at all assessed time points in both baseline AFP strata. Decreased AFP was associated with longer survival consistently in patients with high baseline AFP and at later time points in patients with low baseline AFP. Early bilirubin decreases were also associated with longer survival. Patients whose NPS phenotype decreased had substantially longer median survival than those with increased phenotype. Conclusions: 1.5.Early post-TARE changes in albumin and AFP were associated with overall survival in this retrospective cohort. These findings support future prospective validation of dynamic biomarker changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.